

# The use of Aquaphor to prevent transepidermal water loss and to maintain electrolyte balance in preterm newborn infants in the first week of life.

<b>Submission date</b> 30/09/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 10/03/2011	<b>Condition category</b> Neonatal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Enitan M Ogundipe

### Contact details

Neonatal Unit  
Chelsea & Westminster Hospital  
369 Fulham Road  
London  
United Kingdom  
SW10 9NH  
+44 (0)20 8746 7881  
enitan.ogundipe@chelwest.nhs.uk

## Additional identifiers

### Protocol serial number

N0060131640

## Study information

## Scientific Title

### Study objectives

Will the use of an emollient (aquaphor) in the first week of life reduce transepidermal water loss (TEWL) in very preterm babies and improve their metabolic and electrolyte balance compared to infants not given the emollient treatment ?

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Study type(s)

Not Specified

### Health condition(s) or problem(s) studied

Neonatal Diseases: Transepidermal water loss (TEWL)

### Interventions

Standard care compared with emollient (aquaphor) therapy in addition to standard care.

### Intervention Type

Drug

### Phase

Not Specified

### Drug/device/biological/vaccine name(s)

aquaphor

### Primary outcome(s)

1. Fluid requirement in 1st week of life
2. Neonatal morbidity: electrolyte balance, metabolic balance, chronic lung disease, treated patent ductus arteriosus

### Key secondary outcome(s))

Not provided at time of registration

### Completion date

31/12/2007

## Eligibility

**Key inclusion criteria**

Not provided at time of registration

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Neonate

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/11/2003

**Date of final enrolment**

31/12/2007

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre****Neonatal Unit**

London

United Kingdom

SW10 9NH

**Sponsor information****Organisation**

Department of Health

# Funder(s)

## Funder type

Government

## Funder Name

Chelsea and Westminster Healthcare NHS Trust (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Abstract results</a>	results			No	No